Standard chemotherapy stem cell transplantation for hodgkin chemotherapy with autologous stem cell transplantation. Medical search. Frequent questions

These EBV+ B cells have numerous non-malignant crippling mutations, often proliferate excessively, and in some cases may transform into EBV+ B cell lymphomas. (wikipedia.org)
AITL comprises 15-20% of peripheral T-cell lymphomas and 1-2% of all non-Hodgkin lymphomas. (wikipedia.org)
Most non-Hodgkin lymphomas (NHL) in children are fast growing, aggressive cancers. (dana-farber.org)
However, there are several slow growing B-cell lymphomas that occur in this young age group. (dana-farber.org)
There are also rare T-cell lymphomas that are more frequently seen in adults but occasionally occur in children. (dana-farber.org)
There is no standard therapy for these lymphomas in children. (dana-farber.org)
The belief that T-cell lymphomas have a worse prognosis than B-cell lymphomas remains controversial. (oncolink.org)
REAL/WHO- [6] - classification includes leukemias and lymphomas, with 3 categories based on lineage and morphology (Hodgkin, B cell, and T/NK cell). (oncolink.org)
MCL represents 2-10% of all non-Hodgkin lymphomas. (medscape.com)
[ 6 ] In the International Lymphoma Classification Project, it accounted for 8% of all non-Hodgkin lymphomas (NHLs). (medscape.com)
Lymphomas are cancers that involve white blood cells, and can be divided depending on the type of cell involved, either B-lymphocytes or T-lymphocytes. (rarediseases.org)
Mantle cell lymphoma belongs to a group of diseases known as non-Hodgkin's lymphomas, which are related malignancies (cancers) that affect the lymphatic system. (rarediseases.org)
At times, very advanced and nonresponsive lymphomas may be treated using a bone marrow transplant (marrow is the soft tissue in the centre of large bones that produces white and red blood cells and platelets) or stem-cell transplantation (the cells that develop blood). (lymphoma.ca)
Patients with lymphomas that are difficult to treat or resistant to standard therapy may benefit from chemotherapy or radiation therapy given in very high doses (myeloablative therapy). (lymphoma.ca)
Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
With few exceptions, stem cell transplantation is usually reserved for patients with aggressive lymphomas after incomplete remission or relapse. (msdmanuals.com)
If you're seeing these very aggressive, large cell lymphomas, follow them very closely and be prepared for the next type of treatment they may need. (onclive.com)
Now, molecular studies are looking at large cell lymphomas that really break them down into multiple different groups, perhaps 5 different types of large cell lymphoma, based on their genetic signature. (onclive.com)
Zhang QY, Foucar K. Bone marrow involvement by Hodgkin and non-Hodgkin lymphomas. (medscape.com)
MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. (pharmateca.ru)

Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
The most common non-Hodgkin lymphoma diagnoses in children are Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma. (dana-farber.org)
Primary central nervous system lymphoma in children is usually of the diffuse large B-cell lymphoma type. (dana-farber.org)
Malignant blast cells (i.e. diffuse large B-cell lymphoma) are fast-growing and result in aggressive disease, whereas malignant mature lymphocytes (i.e. follicular lymphoma) behave indolently. (oncolink.org)
Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
In diffuse large B-cell lymphoma (DLBCL), it's critical to understand the genetic risk of each individual patient, according to John M. Pagel, MD, PhD, who added that genetic risk can inform up-front and newly expanding options in the relapsed/refractory setting. (onclive.com)

The Dana-Farber/Boston Children's Stem Cell Transplant Center offers autologous and allogeneic stem cell transplants and is active in researching new stem cell techniques. (dana-farber.org)
HDC with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. (bdbiosciences.com)
Most patients with Hodgkin's Lymphoma are cured with first-line chemotherapy however, a small proportion of patients are non-responders or relapse, who have to undergo an autologous stem cell transplant. (thepatientschannel.com)
The optimal cell dose for a single autologous transplant is still an unanswered question. (bloodline.net)
This study is seeking participants who are unable or unwilling to undergo an autologous stem cell transplant ation (when doctors put healthy blood cells back into your body) or CAR-T immune cell therapy. (survivornet.com)
In a univariate analysis, factors significantly associated with improved DFS included absence of B symptoms (fever, night sweats and unexplained weight loss) at transplant, response to pre-transplant salvage chemotherapy, less tumor bulk at time of transplant, and fewer prior treatment regimens. (umn.edu)
Stepwise multivariate analysis showed that the absence of B symptoms at time of transplant was independently and significantly associated with improved DFS after transplantation. (umn.edu)
CBV with autologous stem cell support can produce durable remissions with acceptable toxicity in a substantial proportion of patients who are asymptomatic at time of transplant. (umn.edu)
Following that, patients may be eligible for a stem cell transplant, and/or an extended course of immunotherapy that is meant to prolong cancer remission. (rarediseases.org)
A syngeneic transplant is when the cells are donated by an identical twin. (lymphoma.ca)
To combat this problem, the patient receives a bone marrow or a stem-cell transplant. (lymphoma.ca)
What is the Difference Between a Bone Marrow Transplant and a Stem-cell Transplant? (lymphoma.ca)
Harvesting is the procedure by which the bone marrow or stem cells are obtained in preparation for the transplant. (lymphoma.ca)
In a bone marrow transplant, the stem cells are withdrawn from the bone marrow under general anesthesia by inserting a needle into a bone in the pelvic region, called the iliac crest. (lymphoma.ca)
Stem cells or bone marrow harvested from the patient (autologous transplant) are generally preserved and stored in a freezer until ready for use. (lymphoma.ca)
Stem cells or bone marrow derived from a donor (allogeneic transplant) are usually collected immediately before use and not stored for any length of time. (lymphoma.ca)
Coleman Lindsley (right) and Benjamin Ebert work to identify patients with MDS who are likely to benefit from stem cell transplant. (dana-farber.org)
Among patients who underwent a stem cell transplant for myelodysplastic syndrome (MDS) - a family of conditions in which bone marrow doesn't produce enough healthy blood cells - outcomes after stem cell transplantation depend on the mutation profile of their disease. (dana-farber.org)
Another study led by Dana-Farber researchers sought to determine how CHIP - a condition in which patients' blood cells carry acquired mutations associated with blood cancers, but the patients themselves are healthy - affects patient outcomes after an autologous stem cell transplant for non-Hodgkin lymphoma . (dana-farber.org)
In another study, Dana-Farber scientists found that when donor stem cells carrying CHIP abnormalities are used in a donor transplant, the abnormalities often remain detectable in the recipient. (dana-farber.org)
A treatment known as anti-T lymphocyte globulin (ATLG), in combination with other drugs, reduced the risk of graft-versus-host disease in patients undergoing a donor stem cell transplant. (dana-farber.org)
On July 31, 2020, the FDA approved tafasitamab in combination with lenalidomide (Revlimid) for patients with relapsed/refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. (onclive.com)
The standard of care has been to try to get patients to an autologous stem cell transplant, if they've relapsed. (onclive.com)
This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. (bioseek.eu)
Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant. (bioseek.eu)
Time trends in risk and risk determinants of non-hodgkin lymphoma in solid organ transplant recipients. (medscape.com)

OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
Autologous stem cell transplantation (ASCT) is an established standard of care treatment to improve survival in multiple myeloma and non-Hodgkin's lymphoma. (bloodline.net)
While much emphasis is placed on improving the efficacy of ASCT via disease specific interventions, the contribution of stem cell mobilization is often overlooked. (bloodline.net)
The benefits of ASCT cannot be achieved without a successful stem cell mobilization, so efforts must also be focused on optimizing stem cell mobilization. (bloodline.net)
Objective To explore the prognostic evaluation of 18 F-FDG PET/CT imaging RECIL standard for patients with non-Hodgkin's lymphoma (NHL) after autologous hematopoietic stem cell transplantation (ASCT) and the comparative study with Lugano standard. (ijrmnm.com)
According to the Lugano standard, all patients were evaluated for efficacy after ASCT. (ijrmnm.com)
Conclusion The RECIL after ASCT can accurately evaluate the prognosis of NHL patients, and the RECIL and Lugano standard have similar prognostic evaluation effects on NHL patients after ASCT. (ijrmnm.com)
San Diego, CA-Although considered a standard of care for patients with newly diagnosed multiple myeloma, the benefit of autologous stem-cell transplantation (ASCT) has been recently questioned as a result of the rapid expansion of novel treatments. (valuebasedcancer.com)

Stem cell transplantation is the treatment of choice, with the allogeneic one being the preference because AITL tends to recur after autologous transplants. (wikipedia.org)
A speciality of our clinic is allogeneic and autologous stem cell Transplantation. (uniklinikum-dresden.de)
Treatment includes chemotherapy and often stem cell transplantation , either from the patient's own bone marrow (autologous) or sometimes from another person's bone marrow (allogeneic). (dana-farber.org)
Outcomes of myelofibrosis (MF) with allogeneic stem cell transplantation (allo-SCT) have improved over the past decade, related in part to advances in supportive treatments and conditioning regimens. (bvsalud.org)
3 Autologous stem cell transplantation almost exclusively uses peripheral blood, while for allogeneic SCT, T-lymphocytes in the peripheral blood could pose some danger. (bdbiosciences.com)
G-CSF is a commonly used mobilizing agent for practically all autologous and a majority of allogeneic HSCTs and is known to increase CD34+ concentration. (bdbiosciences.com)
Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). (nih.gov)
Data suggest that young patients with recurring disease following autologous HSCT, as well as some patients with multiple relapses and selected patients with refractory lymphoma, might benefit from allogeneic HSCT, but relapse remains the major challenge. (nih.gov)
Allogeneic is when the donor's basic cell is almost identical to the patient's as with a close relative (brother or sister). (lymphoma.ca)
Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. (nature.com)

However, most studies lack homogeneity in conditioning regimens used, limiting their ability to assess prognostic factors on transplantation outcomes. (bvsalud.org)

The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
Treatment for primary central nervous system lymphoma requires high doses of chemotherapy that enter the central nervous system, such as high-dose methotrexate and high-dose cytarabine. (dana-farber.org)
Radiation therapy has been used as part of the treatment for this lymphoma in adults but may not be necessary if high dose chemotherapy is used in the treatment plan. (dana-farber.org)
Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patient's blood and immune cell production capacity. (bdbiosciences.com)
Autologous HSCT following high-dose chemotherapy, the standard treatment for adult patients with relapsed HL, is also effective in paediatric patients, but randomized trials showing its superiority to conventional therapy are lacking. (nih.gov)
High-dose chemotherapy (using a different chemotherapeutic agent) and autologous stem cell transplantation (SCT) is considered the treatment of choice in a subset of patients. (wjon.org)
Bone marrow or stem cells that have been removed from a donor are carefully frozen and stored while the patient receives high-dose chemotherapy and sometimes whole-body radiation treatment. (lymphoma.ca)
This means that they receive stem cells (either their own stem cells that were stored prior to myeloablative therapy or stem cells from a donor) to replenish their bone marrow which had previously been destroyed by the high-dose therapy. (lymphoma.ca)
High-dose chemotherapy, with or without myeloablative radiation therapy, is then administered to the patient to destroy the cancerous cells, as well as the healthy cells in the bone marrow. (lymphoma.ca)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. (medscape.com)

The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
Recorded at the annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France. (thepatientschannel.com)

In a phase II trial reported in JAMA Oncology , Locke J. Bryan, MD , and colleagues found that the combination of pembrolizumab with ICE chemotherapy (a regimen including ifosfamide, carboplatin, and etoposide) produced a high rate of complete response in patients with relapsed or refractory classical Hodgkin lymphoma who were candidates for autologous stem cell transplantation (SCT). (ascopost.com)
Even though classical Hodgkin lymphoma is highly curable, the outcome of patients with a refractory or relapsed disease has been disappointing. (wjon.org)
The overall prognosis of patients with relapsing and recurrent classical Hodgkin lymphoma (rrcHL) has been very disappointing until recently. (wjon.org)
The core of classical Hodgkin lymphoma (cHL) management is based on the ABVD therapy combination (doxorubicin, bleomycin, vinblastine, dacarbazine) followed by the recommended form of radiation in the early and advanced stages of the disease [ 1 ]. (wjon.org)
Adcetris) plus nivolumab (Opdivo) consolidation therapy after autologous hematopoietic stem-cell transplantation (HSCT) in patients with high-risk relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). (medivizor.com)
Evaluating the effectiveness and safety of penpulimab in patients with relapsed or refractory classical Hodgkin lymphoma. (medivizor.com)
In a nutshell This study evaluated the effectiveness and safety of penpulimab (AK105) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). (medivizor.com)
Some background Classical Hodgkin lymphoma (cHL) is a cancer of. (medivizor.com)

In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML). (hindawi.com)
Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
Dr. Parameswaran Hari details specific issues in patients with multiple myeloma and lymphoma as well as the issue of stem cell remobilization. (bloodline.net)
Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is revolutionizing the treatment of hematologic malignancies with unprecedented response rates in patients with relapsed/refractory lymphoma, multiple myeloma, and acute lymphoblastic leukemia. (ajmc.com)

For Treatment we use different, state of the art therapy Options as Immune Therapy, Chemotherapy and the treatment with targeted therapies. (uniklinikum-dresden.de)
Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. (hindawi.com)
Moreover, we will review the disadvantages of CAR-T cell therapy and propose several comprehensive recommendations which might guide its development. (hindawi.com)
Fifty-six patients (71%) received post-transplantation maintenance therapy. (bvsalud.org)
[ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
12 months after completion of therapy) may be cured with conventional therapy, those with progressive disease or early relapse (3-12 months) are considered candidates for autologous HSCT. (nih.gov)
The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
In elderly patients or patients in whom autologous transplantation is not possible in the future, melphalan and prednisone (MP) therapy is preferred because of its ease of administration and low toxicity. (medscape.com)
Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied. (frontiersin.org)
Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
After therapy, the frozen marrow or cells are thawed and put back in the body. (lymphoma.ca)
Stem cells, because they divide rapidly, can be killed off by chemotherapy and radiation therapy. (lymphoma.ca)
Therefore, the doses of chemotherapy and radiation therapy used to treat lymphoma are limited due to the risk of damaging these stem cells. (lymphoma.ca)
Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. (nature.com)
Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. (nature.com)
The addition of separate adapter molecules (AMs) specific for tumor antigens and CAR-immune cells targeting these AMs allows a more precise and temporally limited therapy. (nature.com)
An autologous CAR-T or NK cell therapy comprises several steps as shown in Fig. 1 . (nature.com)
Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma. (medivizor.com)
San Diego, CA-Maintenance therapy with lenalidomide (Revlimid) after frontline chemotherapy markedly prolonged progression-free survival (PFS) in patients with high-risk chronic lymphocytic leukemia (CLL), according to interim results from a phase 3 study presented at the 2016 American Society of Hematology meeting. (valuebasedcancer.com)
The survival rate in these patients was better than would have been expected with standard therapy. (dana-farber.org)
Such treatments now include CAR T-cell therapy, polatuzumab vedotin (Polivy), tafasitamab-cxix (Monjuvi) and selinexor. (onclive.com)
Case presentation Here, we report a case of a refractory MCL in a patient who had relapsed after conventional chemotherapy and autologous CAR T cell therapy. (bmj.com)
Conclusions This case suggests that haplo-CAR T cell therapy can be effective in controlling lymphoma that failed to respond to autologous CAR T cell therapy and overcome limitation of autologous CAR T cells, thus may be one possible regimen before the era of off-the-shelf "universal" CAR T cell therapy. (bmj.com)
Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. (medscape.com)
The process for administering CAR T-cell therapy is complex, with multiple steps including CAR T-cell manufacturing, lymphodepleting chemotherapy, cellular therapy infusion, and management of short-term and long-term toxicities. (ajmc.com)
Pharmacists are intricately involved in the process of providing CAR T-cell therapy both at the organizational level of budgeting and coordinating therapy and in direct patient care roles providing counseling and support for adverse effect management. (ajmc.com)
Research in CAR T-cell therapy is expected to improve tolerability and expand indications to more types of malignancies and earlier phases of disease. (ajmc.com)
Managed care professionals should have an understanding of the clinical trial data and place in therapy in lymphoma, myeloma, and acute lymphoblastic leukemia as well as guideline recommendations for adverse effect management associated with CAR T-cell therapies. (ajmc.com)
Chimeric antigen receptor (CAR) T-cell therapy is designed to enhance the body's immune system to effectively kill malignant cells. (ajmc.com)
1 CAR T-cell therapy pivotal trials demonstrated unprecedented overall response rates (ORRs) and complete responses (CRs) that led to the FDA approval of 5 CAR T-cell products: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), brexucabtagene autoleucel (brexu-cel), and idecabtagene vicleucel (ide-cel). (ajmc.com)
In addition, challenges related to manufacturing a patient-specific product, need for inpatient administration in a tertiary care setting, high costs and inadequate reimbursement have limited access to CAR T-cell therapy. (ajmc.com)
2,3 Cellular therapy centers, manufacturers, payers, and policy makers will need to work together to address barriers to care as new CAR T-cell products with improved efficacy and tolerability are approved for use in more diverse malignancies. (ajmc.com)
Some patients with extensive small cell lung cancer also receive radiation therapy. (yourcancercare.com)

In addition, the isolation and storage of umbilical cord blood hematopoietic stem cells have been used to rebuild the immune system for the treatment of hematological malignancies and might be promising for the dynamic equilibrium expansion of functional T cells [ 12 ]. (hindawi.com)
and those transplanted with autologous hematopoietic stem cells. (cancernetwork.com)

Autologous is when the patient's own stem cells are removed from his or her bone marrow or bloodstream. (lymphoma.ca)
The harvested stem cells or bone marrow (obtained from either the patient's own healthy cells or from a donor) are then transplanted intravenously into the bloodstream of the patient. (lymphoma.ca)
Cancer immunotherapies aim to support or boost the patient's immune system to enable the effective clearance of cancer cells. (nature.com)
First, T or NK cells are isolated from patient's or donor's blood. (nature.com)
When DILI is suspected during chemotherapy, exclusion of viral hepatitis is mandatory, which can be achieved by measuring markers of hepatitis viruses, including HEV, and examining the patient's detailed medical history. (journaltocs.ac.uk)
1. Definition: GVHD develops when the donor's immune cells mistakenly attack the patient's normal cells. (drcremers.com)

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
Patients received two cycles of pembrolizumab at 200 mg on day 1 with standard salvage ICE chemotherapy every 21 days, followed by stem cell mobilization and collection, and then one cycle of pembrolizumab alone followed by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT) response assessment. (ascopost.com)

Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
In the U.S. investigator-initiated multicenter study, 37 evaluable patients with relapsed or refractory disease after one or two lines of chemotherapy were enrolled between April 2017 and October 2020. (ascopost.com)
Short time to relapse and refractory disease at the time of autologous HSCT remain the most important risk factors. (nih.gov)
However, in these patients, conventional-dose chemotherapy regimens induce low remission rates, resulting in long-term remissions in approximately 40-50% of relapsed patients and in up to 25-30% of those with primary refractory disease. (wjon.org)

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
3 Following exogenous stimulation, such as chemotherapy or using growth factors such as granulocyte colony stimulating factor (G-CSF) and filgrastim, the number of HSCs in the peripheral blood increases, either becoming on par or even exceeding the number in the bone marrow. (bdbiosciences.com)
CD34, a transmembrane phosphoglycoprotein, is present on immature hematopoietic precursor cells and all hematopoietic colony-forming cells in bone marrow and blood, including unipotent and pluripotent progenitor cells. (bdbiosciences.com)
Flow cytometric enumeration of CD34+ HSCs and progenitor cells is an established method for the evaluation of bone marrow and stem cell grafts. (bdbiosciences.com)
Bone marrow transplantation , 16 (1), 13-18. (umn.edu)
Lymphatic tissues also include the thymus, a relatively small organ behind the breastbone that is thought to play an important role in the immune system until puberty, as well as the bone marrow, which is the spongy tissue inside the cavities of bones that manufactures blood cells. (rarediseases.org)
With types of NHL that have spread to the bloodstream or bone marrow, it may be difficult to obtain uncontaminated cells or cells that can be used, even after treating them in a laboratory to remove or kill the NHL cells. (lymphoma.ca)
This process kills all or most normal stem and bone marrow, while destroying cancer cells. (lymphoma.ca)
However, this can potentially destroy all the stem-cells in the bone marrow and leave the patient at very high risk for infection. (lymphoma.ca)
There are two different types of transplants: bone marrow transplants and peripheral blood stem-cell transplants (PBSCTs). (lymphoma.ca)
In bone marrow transplants, the stem cells are taken from the bone marrow. (lymphoma.ca)
PBSCTs are now more commonly performed than bone marrow transplants, as the procedure is easier and the body is able to regenerate new stem cells faster. (lymphoma.ca)
Hodgkin Lymphoma Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
The cancer can spread to almost any organ or tissue in the body, including the liver, bone marrow (the spongy tissue inside the large bones of the body that makes blood cells), and spleen. (marystolfacancerfoundation.org)
Plasma cell myeloma is a malignant proliferation of plasma cells in bone marrow associated with an M-protein in serum and/or urine. (jahjournal.org)
In bone marrow examination, most cases show the mature pattern of neoplastic plasma cells. (jahjournal.org)
A bone marrow examination was performed and revealed that around 37% of plasma cells in the aspirate had significant dysplastic changes, were multinucleated, and exhibited basophilic cytoplasm [Figure 1] . (jahjournal.org)
The bone marrow biopsy showed 100% cellularity with diffuse infiltration by mononucleated cells and some multinucleated forms [Figure 2] . (jahjournal.org)
FISH study performed on bone marrow cells showed positive for IGH/CCND1 fusion (t[11;14]) and monosomy 13 (D13S319/LAMP1) which were detected in 34% and 48% of cells, respectively [Figure 3] . (jahjournal.org)

Dr Anna Sureda from the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain discusses the standard of care for Hodgkin's Lymphoma and potential consolidation therapies. (thepatientschannel.com)
She intends to contribute to the growing body of literature in the field of radiation oncology with the ultimate goal of influencing the standard of care as well as the prevention and management of long term treatment related toxicity. (mdanderson.org)
Guideline] NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. (medscape.com)

Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. (wikipedia.org)
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
As stated by the investigators, "To our knowledge, this is the first clinical trial designed to investigate concurrent treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or refractory classic[al] Hodgkin lymphoma in patients destined for an autologous SCT. (ascopost.com)
Twenty-three (37%) patients remain in continuous clinical remission 1.3 to 7.7 years (median 3.8 years) after transplantation. (umn.edu)
In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany. (nature.com)
Clinical scientists continue to observe superior survival of patients treated with combined chemotherapy and radiation approaches, yet the mechanisms behind this synergistic therapeutic approach are not fully understood. (mdanderson.org)
Computed tomography-based tumor volume in non-Hodgkin lymphoma: clinical correlation and comparison with magnetic resonance imaging. (medscape.com)
The progress that has been made in the treatment of small cell lung cancer has resulted from the development of multi-modality treatments, new anti-cancer agents and participation in clinical trials. (yourcancercare.com)
Future progress in the treatment of small cell lung cancer will result from continued participation in appropriate clinical trials. (yourcancercare.com)
Clinical trials continue to evaluate new drugs and new combinations of drugs in an effort to improve upon the treatment results achieved with standard chemotherapy regimens. (yourcancercare.com)

The investigators concluded, "Results suggest that the addition of pembrolizumab to ICE chemotherapy was well tolerated and highly effective in comparison with prior reports of chemotherapy-only regimens, supporting further investigation in patients with relapsed or refractory classic[al] Hodgkin lymphoma eligible for an autologous SCT. (ascopost.com)

We aimed to identify the risk factors that predict transplantation outcomes in patients with MF who underwent matched or mismatched allo-SCT using a uniform myeloablative conditioning regimen consisting of busulfan and fludarabine with tacrolimus and methotrexate-based graft-versus-host disease prophylaxis. (bvsalud.org)
There is scarce data on MM patients with more than one high-risk cytogenetic aberration (ie, ultra- high-risk MM). This study was conducted to evaluate outcomes of newly diagnosed MM patients with ultra-high-risk MM who underwent autologous hematopoietic stem cell transplantation (autoHCT). (bvsalud.org)
The patient achieved a very good response to vincristine, doxorubicin (Adriamycin), and dexamethasone chemotherapy, and then he underwent autologous stem cell transplantation twice in 2007 and 2012. (jahjournal.org)

This pharmacologically induced egress of HSCs into peripheral blood, called mobilization, is utilized as the preferred strategy for generating HSCs for transplantation. (bdbiosciences.com)

The Nigro protocol, by the way, consists of combined chemotherapy and radiation and is still the standard of care for anal cancer. (sciencebasedmedicine.org)

DLBCL is a type of non-Hodgkin lymphoma (NHL). (survivornet.com)

The trial met its primary endpoint, showing superior overall survival (OS) with Opdivo plus Yervoy versus chemotherapy (pemetrexed and cisplatin or carboplatin) in all randomized patients. (pharmiweb.com)
Currently the standard treatment for extensive small cell lung cancer is chemotherapy using a combination of chemotherapy drugs, typically cisplatin or carboplatin combined with etoposide or irinotecan. (yourcancercare.com)

1 Improvements in transplantation techniques, including the wider use of cell selection, have contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. (bdbiosciences.com)

The nature of disease (indolent vs. aggressive) is correlated to the stage of lymphocytic differentiation of the malignant cells. (oncolink.org)
Non-Hodgkin lymphoma is not one disease but rather a category of lymphocyte cancers with a number of subgroups largely divided into aggressive and indolent types. (msdmanuals.com)
If we see those, [we know] that this is usually a very aggressive large cell lymphoma. (onclive.com)
Background The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. (bmj.com)
MCL can be both indolent or aggressive, in either case it responds poorly to chemotherapy and consequently the aggressive form has a dismal prognosis assessed by incorporating Ki-67 proliferation index and Mantle Cell International Prognostic Index scores. (bmj.com)

The Epstein-Barr virus (EBV) is observed in the majority of cases, being identified in the reactive (i.e. non-malignant) B-cells that comprise part of the polymorphous infiltrate of AITL. (wikipedia.org)
The other cell types in these infiltrates, including the malignant TFH cells, are EBV negative. (wikipedia.org)
MCL is a B-cell lymphoma that develops from malignant B-lymphocytes within a region of the lymph node known as the mantle zone. (rarediseases.org)
Normally, potentially malignant cells are continuously eliminated by the immune system, but cancer cells can accumulate certain mutations, which allow them to escape these mechanisms [ 2 ]. (nature.com)
CAR-modified immune cells are expanded until sufficient cell numbers are attained and are adoptively transferred into the patient to fight malignant cells. (nature.com)

However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
Various biological processes including immunoreaction of infection, tumor prevention, and human aging could cause telomere damage, tumor-related stress responses, and T regulatory (Treg) cells activation, which even trigger T cell senescence showing the distinctive phenotypic and functional alternation [ 9 , 10 ]. (hindawi.com)
elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
CAR-expression on T or NK cells allows them to specifically target cancer cells via recognition of tumor associated antigens. (nature.com)
Binding of a tumor antigen via the scFv activates the T cell in a major histocompatibility-independent manner which leads to a cytotoxic response [ 3 ]. (nature.com)
I. To determine if treatment with the irradiated cells induces an immune response targeting tumor associated epitopes. (bioseek.eu)
Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)

Rare cases of plasma cell myeloma with morphological variants have been reported. (jahjournal.org)
Here we report a case of a plasma cell myeloma with a very unusual presentation diagnosed based on flow cytometry, immunohistochemistry, and cytogenetic studies. (jahjournal.org)
A75-year-old man was initially diagnosed in 2007 with IgA kappa plasma cell myeloma. (jahjournal.org)

30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
this is used in both autologous and allogenic HSCT. (bdbiosciences.com)
According to patient selection criteria, overall and disease-free survival rates after autologous HSCT are 43-95% and 31-70%, respectively. (nih.gov)
COHORT I: Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous hematopoietic stem cell transplantation (HSCT), patients receive initial treatment with IHC. (bioseek.eu)

The first-line treatment typically includes chemotherapy combined with immunotherapy, which is a combination of medications that destroy the cancer cells. (rarediseases.org)

Novel understanding in the interaction between immune system and cancer cells of the patient holds great promise for immunotherapy development [ 4 - 6 ]. (hindawi.com)
Children and teens with rare childhood non-Hodgkin lymphoma are treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center through the Childhood Lymphoma Program in our Childhood Hematologic Malignancy Center . (dana-farber.org)
A favorite claim made by cancer quacks (and quacks of all varieties, actually) is that chemotherapy doesn't work. (sciencebasedmedicine.org)
Note how Adams portrays screening for cancer and chemotherapy as a deadly scam designed solely to enrich the "cancer industry" as it kills patients. (sciencebasedmedicine.org)
There is not a single cancer patient that has ever been cured by chemotherapy. (sciencebasedmedicine.org)
When I first encountered that cartoon a few years ago, I was a bit surprised that even Mike Adams would go so far as to make such an absolutist statement that not a single person has ever been cured of cancer by chemotherapy in the entire history of "western medicine. (sciencebasedmedicine.org)
From a cancer patient population and public health perspective, cancer chemotherapy (chemo) has been a major medical advance . (sciencebasedmedicine.org)
Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, which is a form of cancer that affects the lymphatic system. (rarediseases.org)
Immune checkpoint inhibitors are safe and effective for people living with HIV who have metastatic non-small cell lung cancer (NSCLC), according to data presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting. (ascopost.com)
Marrow or cell transplantation is done to replace healthy cells that have been destroyed by cancer treatment. (lymphoma.ca)
Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. (wustl.edu)
Non-Hodgkin lymphoma is the 2nd most common cancer in HIV-infected patients Non-Hodgkin lymphoma AIDS-defining cancers in patients infected with HIV are Kaposi sarcoma Lymphoma, Burkitt (or equivalent term) Lymphoma, immunoblastic (or equivalent term) Lymphoma, primary, of central nervous system read more , and some AIDS patients present with lymphoma. (msdmanuals.com)
For decades the only available cancer treatments were surgical resection as well as chemotherapy and/or radiotherapy [ 1 ]. (nature.com)
Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2- metastatic breast cancer. (medivizor.com)
SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). (medivizor.com)
The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these. (medivizor.com)
Treatment of blood-related, or hematologic, cancers is seizing on insights into the basic genetic wiring of cancer cells and the body's system for finding and attacking those cells. (dana-farber.org)
and finally, radiosurgery in combination with immunotherapy for non-small cell lung cancer and melanoma. (pennmedicine.org)
In an interview with OncLive , Pagel, chief of the Hematologic Malignancies Program, and director of the Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discussed current treatment approaches in frontline and relapsed/refractory DLBCL and provided insight on some of the agents that are generating excitement in the relapsed/refractory setting. (onclive.com)
The cancer cells in Hodgkin's disease look a certain way under a microscope. (marystolfacancerfoundation.org)
If the lymph nodes don't feel normal, a doctor may need to cut out a small piece and look at it under the microscope to see if there are any cancer cells. (marystolfacancerfoundation.org)
Cancer Stat Facts: Non-Hodgkin Lymphoma. (medscape.com)
When small cell lung cancer has spread to both lungs or is detectable beyond the lungs, it is referred to as extensive . (yourcancercare.com)
The following is a general overview of the treatment of extensive small cell lung cancer. (yourcancercare.com)
Patients with extensive disease small cell lung cancer are rarely curable with currently available standard treatment strategies although many patients experience a response to treatment. (yourcancercare.com)
While some progress has been made in the treatment of small cell lung cancer, better treatment strategies are clearly needed, as the majority of patients still experience disease recurrence. (yourcancercare.com)
There are several areas of active exploration aimed at improving the treatment of small cell lung cancer. (yourcancercare.com)
Targeted therapies are anticancer drugs that interfere with specific pathways involved in cancer cell growth or survival. (yourcancercare.com)
and still others stimulate the immune system to recognize and attack the cancer cell. (yourcancercare.com)

It is postulated that the originating cell for AITL is a mature (post-thymic) CD4+ T-cell that arises de novo, or that the disease has a premalignant subtype. (wikipedia.org)
citation needed] The typical patient with angioimmunoblastic T-cell lymphoma (AITL) is either middle-aged or elderly, and no gender preference for this disease has been observed. (wikipedia.org)
The current guidelines for the treatment of Hodgkin lymphoma rely mostly on the stage of the disease at first presentation and the prognostic factors, which may be favorable or unfavorable. (wjon.org)
Earlier application of transplantation or development of additional effective antineoplastic modalities will be required to improve the results of transplantation for patients with advanced Hodgkin's disease. (umn.edu)
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. (medscape.com)
HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. (medscape.com)
While effective, broad use of CAR T-cell therapies is limited by potential for life-threatening toxicities, challenges related to manufacturing a patient-specific product, high costs and inadequate reimbursement, and incomplete or unsustained disease response. (ajmc.com)

The addition of rituximab (Rituxan) to standard CHOP-based chemotherapy represented a major advance in the frontline treatment of patients with DLBCL. (onclive.com)

An accurate measurement of CD34 is critical for dose requirement protocols in stem cell transplantation. (bdbiosciences.com)
5 An incorrectly high result could lead to an infusate with less than the recommended threshold dose of CD34+ cells. (bdbiosciences.com)
Identifying optimal cell dose targets, recognizing risk factors for mobilization failures, and creating risk adapted approaches are just some of the strategies being developed based on our current knowledge. (bloodline.net)

Thirty-six patients (46%) achieved MRD-negative ≥VGPR at day +100 after autoHCT, and 40 patients (51%) did so at best post-transplantation response. (bvsalud.org)

How do Stem-cell Transplants Work? (lymphoma.ca)

However, approximately 50% of patients relapse after transplantation. (thepatientschannel.com)
Chemotherapy was resumed without any subsequent relapse of hepatic enzyme elevation. (journaltocs.ac.uk)

The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. (nature.com)
One way to achieve this is to genetically modify immune cells, mainly T cells and recently also natural killer (NK) cells, to express chimeric antigen receptors (CARs). (nature.com)
Furthermore, the so-called adapter CARs have been developed by splitting antigen recognition and CAR-immune cell activation. (nature.com)
Chimeric antigen receptor-modified T (CAR T) cells exhibit very effective function in elimination of relapsed/refractory B-cell lymphoid malignancies, we investigated their use in a patient with relapsed MCL. (bmj.com)

As stated by the investigators, "The addition of pembrolizumab to ICE chemotherapy did not negatively affect stem cell mobilization or collection or engraftment, similar to prior experience in this patient population and setting. (ascopost.com)
Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC. (medivizor.com)

Serum Levels of the Chemokine CXCL13, Genetic Variation in CXCL13 and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. (medscape.com)

Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)

Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
Mantle cell lymphoma (MCL) is recognized in the Revised European-American Lymphoma and World Health Organization classifications as a distinct clinicopathologic entity. (medscape.com)
Mantle cell lymphoma (MCL) is a type of non-Hodgkin B cell lymphoma with a distinctive molecular marker cyclin D1 that is constitutively overexpressed in almost all cases. (bmj.com)

The diagnosis and treatment facilities we offer our patients are of the highest standard. (uniklinikum-dresden.de)
T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. (hindawi.com)
Reprogramming is a promising treatment, which redifferentiates T-induced pluripotent stem cells (T-IPSCs) into naïve and cytotoxic T cells or dedifferentiates within their own lineage [ 13 ]. (hindawi.com)
Learn more about childhood non-Hodgkin lymphoma , including diagnosis and treatment . (dana-farber.org)
Standard first-line treatment consists of chemoimmunotherapy. (medscape.com)
Meanwhile, the real quackery is found in the pushing of toxic chemotherapy chemicals that are injected into the bodies of patients and called "treatment" when they should really be called "torture. (sciencebasedmedicine.org)
The development in the treatment of Hodgkin lymphoma has been an amazing multidisciplinary effort throughout history. (wjon.org)
Low frequency of differentiated CD3 + CD27 - CD28 - T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients. (frontiersin.org)
In a trial involving older patients with untreated secondary AML, CPX-351 - an agent that combines the chemotherapy drugs cytarabine and daunorubicin at a 5:1 ratio - produced a longer median survival than did the standard treatment of the drugs in a 7:3 ratio. (dana-farber.org)
It's important to understand if it's a germinal center or non-germinal center large cell lymphoma because it's important for prognosis and may be important for treatment and survival. (onclive.com)
Which medications in the drug class Antineoplastic Agents, mTOR Kinase Inhibitors are used in the treatment of Non-Hodgkin Lymphoma (NHL)? (medscape.com)
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version. (medscape.com)
This preventive treatment-called prophylactic cranial irradiation-is usually reserved for patients who have had a good response to chemotherapy. (yourcancercare.com)

The stem cells are separated from other components of the blood in a process called apheresis, with the rest of the blood being returned to the patient. (lymphoma.ca)
Participants and expert faculty interact with talks about new standards of patient care. (pennmedicine.org)
The patient received multiple molecularly targeted therapies, including targeting BTK and BCL2, and haplo-identical CAR T (haplo-CAR T) cells from her daughter without previous allo-hematopoietic stem cell transplantation. (bmj.com)

It is noted that T cell has great potential for immunotherapy of hematological malignancies. (hindawi.com)
In the CheckMate -743 trial, this dual immunotherapy combination demonstrated a clinically meaningful improvement in survival over the standard of care, with 41% of patients who received Opdivo plus Yervoy still alive at two years, compared to only 27% with chemotherapy," said Abderrahim Oukessou, M.D., vice president, thoracic cancers development lead, Bristol Myers Squibb. (pharmiweb.com)

However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies. (hindawi.com)
However, from the beginning of puberty after thymus degeneration, human cytomegalovirus (HCMV) persists due to the chronic activation of cytomegalovirus in humans causing repeated activation of T cells, which is considered the driving factor of human immune aging [ 9 ]. (hindawi.com)
Prior to infusion of the CAR-modified immune cells, lymphodepletion is performed in most therapeutic settings to allow efficient cell engraftment [ 10 ]. (nature.com)
CAR T-cell therapies are limited by the potential to cause life-threatening toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). (ajmc.com)

Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells. (medscape.com)

Clonal T-cell receptor gene rearrangements are detected in 75% of cases, and immunoglobin gene rearrangements are seen in 10% of cases, and these cases are believed to be due to expanded EBV-driven B-cell populations. (wikipedia.org)
Translocations are thought to occur during normal gene rearrangements (Ig, T-cell receptor). (oncolink.org)
Classical " CARs consist of an extracellular binding domain mostly derived from a monoclonal antibody fragment (single-chain variable fragment-scFv), which is linked to intracellular binding domains of the T-cell receptor complex. (nature.com)

Single-agent chemotherapy improved the average survival to four months and the development of combination chemotherapy regimens has further increased the average survival to approximately nine months with some patients surviving two years or longer. (yourcancercare.com)

Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT, formerly known as "angioimmunoblastic lymphadenopathy with dysproteinemia": 747 ) is a mature T-cell lymphoma of blood or lymph vessel immunoblasts characterized by a polymorphous lymph node infiltrate showing a marked increase in follicular dendritic cells (FDCs) and high endothelial venules (HEVs) and systemic involvement. (wikipedia.org)
The polymorphous infiltrate consists of lymphocytes of moderate size with pale/clear cytoplasm and smaller reactive lymphocytes, eosinophils, histiocytes, plasma cells, and follicular dendritic cells. (wikipedia.org)
Polyclonal plasma cells and CD21+ follicular dendritic cells are also seen. (wikipedia.org)

300 mg/m 2 ), and etoposide (900 mg/m 2 ) (CBV) followed by autologous stem cell transplantation. (umn.edu)

Twenty-six patients were infused with CART cells (median 81 days after leukapheresis) and were analyzed for the overall response (OR) 3 months later. (frontiersin.org)
p=0.002), demonstrating a median OS of 18.1 months vs. 14.1 months for platinum-based standard-of-care chemotherapy. (pharmiweb.com)

Six such CAR-T cell therapies are approved by the Food and Drug Administration. (wustl.edu)
A compound named ABL001, designed to block a key site in the abnormal cell protein BCR-ABL, produced strong responses in a phase 1 trial involving patients with CML that failed to succumb to previous targeted therapies. (dana-farber.org)

Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3 + CD4 + T helper and CD3 - CD56 + NK cell counts, while cytotoxic CD3 + CD8 + T cell counts were similar. (frontiersin.org)
DLBCL has been, largely, a success story for us over the past years because we are now able to provide cures to at least 60% of patients with large cell lymphoma. (onclive.com)
While we believe there's significant role for that [regimen], primarily in primary mediastinal DLBCL, the standard of care for the vast majority of patients continues to be R-CHOP in the frontline setting. (onclive.com)

For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
One to two days before your stem cell infusion, you'll take a regimen of drugs to help prevent GVHD. (drcremers.com)

Anatomy24

Organisms4

Diseases51

Chemicals and Drugs52

Analytical, Diagnostic and Therapeutic Techniques and Equipment91

Psychiatry and Psychology1

Phenomena and Processes26

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena2

Humanities1

Information Science4

Named Groups5

Health Care26

Geographicals1

Lymphomas20

Diffuse large B-10

Transplant26

ASCT9

Allogeneic10

Conditioning regimens1

High-dose14

Blood and marrow transplantation2

Classical Hodgkin8

Multiple myeloma4

Therapy34

Hematopoietic stem2

Patient's6

Salvage2

Refractory disease4

Bone19

Oncology3

Clinical10

Relapsed or refractory1

Underwent3

Peripheral-blood1

Combined chemotherapy and radiation1

Type of non-Hodgkin1

Cisplatin or carboplatin2

Conventional1

Aggressive5

Malignant5

Tumor7

Plasma Cell My3

HSCT4

Includes chemotherapy1

Cancer30

Disease7

Rituximab1

Dose3

Post-transplantation1

Transplants1

Relapse2

Antigen5

Pembrolizumab2

Lymphoma risk1

Radiotherapy1

Mantle3

Treatment13

Patient3

Immunotherapy2

Immune4

Hodgkin's Lymphoma1

Receptor3

Survival1

Follicular3

Etoposide1

Median2

Therapies2

DLBCL3

Infusion2